Engineered immune cells take on Hard-to-Treat sarcomas
NCT ID NCT04433221
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a combination of specially engineered immune cells (CAR T cells) and a vaccine for people with sarcoma that has come back or spread. The goal is to see if the treatment is safe and can help shrink tumors. About 20 participants will receive the therapy along with low-dose chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR T cells and sarcoma vaccines
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced or returning sarcoma.
- What could go wrong
- This is a very early, small trial (20 people) testing safety first. The therapy may not shrink tumors, and side effects from the immune response could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Geno-Immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can engineered immune cells tackle childhood sarcoma?
- Can a Patient's own immune cells be engineered to fight a rare sarcoma?
- Can a Patient's own immune cells fight advanced sarcoma?
- Could a massive tissue bank unlock sarcoma's secrets?
- Can a new protein drug shield kids with cancer from dangerous infections?